title: [Prostate-specific antigen for treatment monitoring].
abstract: Today, most incident prostate cancer cases are diagnosed in early and thus potentially curable stages because of the determination of prostate-specific antigen (PSA). Treatment monitoring is another important aspect of the tumor marker PSA. In this article, contemporary recommendations for the use of PSA in treatment monitoring are discussed in the settings of active surveillance, radical prostatectomy and radiotherapy.
authors.affiliation: Martini-Klinik, Prostatakarzinom-Zentrum, Universitätsklinik Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Deutschland. graefen@uke.de
authors.forename: M
authors.initials: M
authors.lastname: Graefen
authors.forename: M
authors.initials: M
authors.lastname: Fröhner
authors.forename: M
authors.initials: M
authors.lastname: Wirth
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000097:blood*; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000628:therapy*
chemical_list: D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D017430:Prostate-Specific Antigen